Welcome to The Medical Roundtable

Expert Experience Interpreting Evidenced-Based Medicine.

Our experts provide their decades of clinical practice and trial experience in a conversational based format that create a compelling discussion.

Don't miss our Clinical Implications and QuizBank to help your improve your knowledge and practice.

Heard at the Roundtable

  • “[Redistribution of abdominal fat is] one of the most rewarding things that we can see, as physicians caring for these patients, because we know that ... means we’re going to see gradual improvements in the HDL and triglycerides over time.”
    ~ Malissa Wood, MD

  • “We have substantial outcomes data with spironolactone and eplerenone; eplerenone in the post-MI patient, spironolactone more so in the Class III or Class IV heart failure patient. Clearly there has been a renaissance for the drugs.”
    ~ Bill Frishman, MD

  • "The difference between a prevalence of disease in patients with normal results or normal testing was in the order of 15% to 20%, which really questions how much better testing is than just flipping a coin and whether it might be just as well to proceed with angiography."
    ~ Mario Garcia, MD

  • "According to the ACC/AHA guidelines, routine exercise testing in the asymptomatic patient is a class III indication and therefore not recommended because the information you get is going to be more confusing and may lead to unnecessary further testing that could lead to complications."

    Joseph Alpert

  • "Fibromyalgia is undoubtedly a valid condition characterized by widespread body pain as well as variable other symptoms, which can include fatigue; sleep disturbance; mood disorders; and other somatic symptoms such as headache, abdominal pain, and hypersensitivity to external stimuli. Fibromyalgia remains a clinical challenge as there is no defining test, symptoms are subjective with variable patient presentation, and ideal treatment is elusive."

    Mary-Ann Fitzcharles